Cargando…
T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis. We previously reported that vaccination with heat shock protein peptide complex-96 (HSPPC-96) improves survival in patients with newly diagnosed GBM (NCT02122822). Especially for patient...
Autores principales: | Zhang, Yang, Mudgal, Poorva, Wang, Liuyang, Wu, Haiyang, Huang, Na, Alexander, Peter B., Gao, Zhixian, Ji, Nan, Li, Qi-Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153824/ https://www.ncbi.nlm.nih.gov/pubmed/32313731 http://dx.doi.org/10.1080/2162402X.2020.1749476 |
Ejemplares similares
-
Immunotherapy with heat shock protein 96 to treat gliomas
por: Li, Chunzhao, et al.
Publicado: (2020) -
Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination
por: Wang, Yi, et al.
Publicado: (2022) -
Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma
por: Eton, Omar, et al.
Publicado: (2010) -
TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma
por: Wang, Guoping, et al.
Publicado: (2021) -
Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)